Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Kentaro Imi"'
Autor:
Hirotsugu Isaka, Yasuhiro Hagiwara, Hirofumi Mukai, Yutaka Matsuyama, Kentaro Imi, Kenichi Watanabe
Publikováno v:
Oncology. 93:315-322
Objective: We assessed the impact of treatment preferences in second-line chemotherapy on breast cancer prognosis using the SELECT BC study. Methods: The SELECT BC study was performed in patients with HER2-negative metastatic breast cancer treated wi
Autor:
Hirotsugu Isaka, Manami Tada, Masakazu Toi, Hironobu Sasano, Takayuki Ueno, Kaisuke Miyamoto, Tomohiro Chiba, Shigeru Imoto, Hiroshi Kamma, Kentaro Imi, Shigehira Saji, Hiroki Itoh
Publikováno v:
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 40(10)
Breast cancer has been suggested to have two distinct driving mechanisms: the hormone receptor and the growth factor receptor pathways. We hypothesized that each driving system produces a different expression pattern of estrogen-regulated genes, such
Autor:
Kentaro Imi, Takayuki Ueno, Manami Tada, Yoshiharu Ishizaka, Hirotsugu Isaka, Hirotaka Suga, Kaisuke Miyamoto, Shigeru Imoto, Tomohiro Shiraishi, Hiroki Ito
Publikováno v:
World journal of surgery. 43(3)
Skin-sparing mastectomy (SSM) and nipple-sparing mastectomy (NSM) are the standard techniques for achieving a cosmetic outcome, but necrosis of a cutaneous flap including the nipple–areolar complex (NAC) is a serious complication. To analyze the ri
Autor:
Kojiro Shimozuma, Kentaro Imi, Hirotsugu Isaka, Ken-ichi Watanabe, Hiroaki Ueo, Takanori Watanabe, Michiko Tsuneizumi, Yukari Uemura, Hiroyoshi Doihara, Shinji Ohno, Hirofumi Mukai, Atsushi Fukuuchi, Hiromitsu Akabane, Masahiro Kashiwaba, Yasuo Ohashi
Publikováno v:
Cancer Research. 75:P3-10
Background: Treatment goals of metastatic breast cancer (MBC) are to prolong survival and improve health-related quality of life (HRQOL). Current standard first-line chemotherapy for MBC are the taxanes or anthracyclines; however treatment-related ad
Autor:
Hirotsugu Isaka, Chikako Shimizu, Noriaki Wada, Takayuki Kinoshita, Kentaro Imi, Masashi Ando, Takashi Hojo, Yasuhiro Fujiwara, Shigeru Imoto, Hiroki Ito
Publikováno v:
The Breast. 22:263-267
Purpose The optimal treatment duration time and the causal relationship between neoadjuvant endocrine therapy and clinical response are not clear. Therefore, we conducted the present study to investigate the potential benefits of neoadjuvant exemesta
Autor:
Natsuko Mizutani, Hiroki Ito, Sachiyo Nomura, Shigeru Imoto, Hiroshi Kamma, Yukiko Shishido-Hara, Hirotsugu Isaka, Kentaro Imi, Eri Tazaki
Publikováno v:
Pathology International
Lobular carcinoma in situ (LCIS) clinically constitutes a risk factor for the subsequent development of either invasive lobular carcinoma (ILC) or invasive ductal carcinoma (IDC). In order to approach the possibility of this common precursor of both
Publikováno v:
Breast Cancer. 19:104-109
Sentinel node biopsy (SNB) is a standard technique for the diagnosis of regional lymph node metastases in clinically node-negative breast cancer patients. In the case of pathologically negative sentinel lymph nodes (SLN), axillary lymph node dissecti
Publikováno v:
European Journal of Surgical Oncology (EJSO). 40:S65-S66
Autor:
Hisanaga, Nomura, Hideyasu, Kawakami, Hisanori, Shimizu, Kentaro, Imi, Hiroki, Ito, Hirotsugu, Isaka, Takao, Shinohara, Shigeru, Nagai, Shigeru, Imoto
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 39(1)
The combination of doxorubicin and cyclophosphamide is a standard chemotherapy regimen for breast cancer. Nausea and vomiting are two common adverse effects that may lead to a significant deterioration in the patient's quality of life. We report on t
Publikováno v:
The Breast. 20:S54-S55